Trial Profile

A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With IgAN, LN, or C3G

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADX-097 (Primary)
Indications IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis
Focus Adverse reactions
Sponsors Q32 Bio

10 Mar 2026 According to a Q32 Biomedia release, company has sold Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics. Akebia will be responsible for its future development and commercialization.
20 Apr 2025 Status changed from discontinued to withdrawn prior to enrolment and the study was closed prior to enrolling any patients.
10 Feb 2025 Status changed from recruiting to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com